Recruiting

New drug combination versus chemotherapy for advanced stomach cancer

Plain-English translation of NCT07315750 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing whether a new three-drug combination—including , , and —works better and is safer than standard chemotherapy (plus , with or without ) for people with advanced stomach or gastroesophageal junction cancer that has high HER2 expression. Participants will be randomly assigned to receive one of these treatment approaches as their first cancer treatment.

Advanced stomach cancer with HER2-high expression is difficult to treat, and doctors need better options to help patients live longer and feel better. This trial aims to see if the new medication combination can be more effective than current standard treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic stomach or gastroesophageal junction cancer that cannot be surgically removed
your cancer has been confirmed to have HER2-high expression
you have not received prior chemotherapy for advanced cancer, or your cancer returned more than 6 months after completing earlier treatment
you are in good enough health to tolerate treatment (ECOG performance status 0 or 1)
you have a life expectancy of at least 12 weeks
you have adequate organ function (kidney, liver, heart, and bone marrow working well enough)

You likely don't qualify if…

you have cancer that has spread to your brain or spinal fluid
you have significant nerve damage in your hands or feet (Grade 2 or higher)
you have active lung disease or severely compromised lung function
you are currently pregnant, breastfeeding, or unwilling to use contraception for 6 months after treatment
you have had another type of cancer in the past 5 years (except certain cancers expected to be cured)

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new three-drug combination or standard chemotherapy with (with or without a fourth drug, depending on a test of your tumor). You will continue treatment until your cancer progresses, you experience unmanageable side effects, or your doctor recommends stopping. Throughout the trial, you will have regular doctor visits to monitor how well the treatment is working and to check for side effects.

AI-generated summary from trial data · Jun 13, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing Cancer Hospital, Beijing, BJ-Beijing